华润医药上半年公司拥有人应占溢利减少20.3%

Core Insights - The company reported total revenue of RMB 131.8668 billion, representing a year-on-year growth of 2.5% [1] - The highest revenue contribution came from pharmaceutical distribution at 79.2%, followed by pharmaceutical manufacturing at 16.6% and retail pharmacy at 4.2% [1] Financial Performance - The company's gross profit amounted to RMB 21.5096 billion, with a year-on-year increase of 2.8%, resulting in an overall gross margin of 16.3% [1] - Net profit was reported at RMB 5.0536 billion, reflecting a decline of 8.8% year-on-year; profit attributable to shareholders decreased by 20.3% to RMB 2.0773 billion [1] - Excluding one-off items, net profit and profit attributable to shareholders saw slight declines of 1.3% and 4.7% respectively [1] - Basic earnings per share were RMB 0.33, and the board declared an interim dividend of RMB 0.072 per share [1]